CBS 2019
CBSMD教育中心
English

推荐文献

科研文章

荐读文献

Radionuclide Image-Guided Repair of the Heart Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study 稳定性冠心病诊断与治疗指南 Variation in Revascularization Practice and Outcomes in Asymptomatic Stable Ischemic Heart Disease Burden of 30-Day Readmissions After Percutaneous Coronary Intervention in 833,344 Patients in the United States: Predictors, Causes, and Cost ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons Generalizing Intensive Blood Pressure Treatment to Adults With Diabetes Mellitus Mode of Death in Heart Failure With Preserved Ejection Fraction A Novel Algorithm for Treating Chronic Total Coronary Artery Occlusion A Novel Familial Cardiac Arrhythmia Syndrome with Widespread ST-Segment Depression

Review Article2017 Oct 24;70(17):2186-2200.

JOURNAL:J Am Coll Cardiol. Article Link

Biological Phenotypes of Heart Failure With Preserved Ejection Fraction

Lewis GA, Schelbert EB, Miller CA et al. Keywords: diastolic dysfunction; ejection fraction; heart failure; heart failure with preserved ejection fraction; myocardial fibrosis; titin

ABSTRACT

Heart failure with preserved ejection fraction (HFpEF) involves multiple pathophysiological mechanisms, which result in the heterogeneous phenotypes that are evident clinically, and which have potentially confounded previous HFpEF trials. A greater understanding of the in vivo human processes involved, and in particular, which are the causes and which are the downstream effects, may allow the syndrome of HFpEF to be distilled into distinct diagnoses based on the underlying biology. From this, specific interventions can follow, targeting individuals identified on the basis of their biological phenotype. This review describes the biological phenotypes of HFpEF and therapeutic interventions aimed at targeting these phenotypes.